Although we found that RUNX3 functioned as a tumor suppressor in gastric cancer, it was reported that RUNX3 served as an oncogene in epithelial ovarian cancer, basal cell carcinoma, and head and neck squamous cell carcinoma. Here, RUNX3 is linked to ovarian carcinoma.